Sangdong Mine Completion Ceremony Marks a Defining Milestone for Almonty
The completion of the Sangdong Mine marks a defining milestone for Almonty and a major step in restoring a globally significant tungsten asset to production.
New Production Sources of Tungsten Are Critical to Maintaining Healthcare Industry Supply
Last Updated, November 5, 2020
Written by Lewis Black
Home » Press Releases »
Healthcare Business Today – https://www.healthcarebusinesstoday.com/ has published an article written by Almonty Industries’ CEO Lewis Black, titled ‘New Production Sources of Tungsten Are Critical to Maintaining Healthcare Industry Supply‘.
Article by Lewis Black, Healthcare Business Today: The trade relations between China and the U.S. have been tense over the last few years. This past January, China and the U.S. signed a “phase one” trade deal, where China agreed to buy an additional $200 billion of American goods and services over the following two years. This deal resulted in the suspension of a planned tariff last December on approximately $162 billion worth of Chinese goods, with an existing 15% duty on imports worth around $110 billion halved.
While the tariffs affect many different types of goods that are imported and exported between the two countries, there is another battle brewing in this growing trade war: Strategic Metals. Rare specialty metals such as tungsten are used in almost all medical devices and medical manufacturing supplies today. Taking into consideration the current COVID-19 pandemic, access to medical manufacturing and supplies is more critical than ever before. Tungsten is listed as the most high risk metal on earth, and is also used in most medical devices and tests we have today. Without it, it would be impossible to run a test as simple as an X-Ray.
China Has Dominated the Medical Supply Chain
For years, China has viewed its dominance in strategic earth metals as potential leverage that can be used against the U.S., which include trade disputes. Research firms and industry observers1 believe China values its strategic metals dominance for geopolitical values over commercial gain.
Rare specialty metals such as tungsten are used for a variety of advanced technologies within the medical industry, including radiation shielding and medical isotope transport and containment. Without tungsten, hospitals would run out of necessary everyday objects such as syringe shields and radioactive source containers.
According to a report2 by consulting firm Horizon Advisory, China cultivated its rare-earth industry through years of state subsidies and is prepared to use it as a geopolitical weapon, which will drastically affect medical supplies in the United States, causing a healthcare crisis. A test as simple as an x-ray could not be performed without tungsten.
China controls the market for nearly 35 precious minerals and metals that are important to the U.S. for medical manufacturing, and tungsten is among them. Furthermore, the second largest tungsten supplier, located in Vietnam, had sourced 6 million metric tons last year. Other regions outside of the U.S. such as Russia, Austria and the United Kingdom are also known to have important tungsten sources.
WHAT’S AT STAKE?
The issue at hand is that China has limited the amount of tungsten exports that can be shipped to the U.S., and this has caused great concern about the overall supply chain of the material, specifically in a time where the United States is dependent on its healthcare system.
In what was seen as an aggressive move, Chinese President Xi Jinping toured a region of the country last year that bills itself as a rare-earths kingdom, and this rhetoric3 was widely viewed as China strong-arming much of the rest of the world and flexing its muscle for strategic metals supply.
What’s at stake is a more bountiful supply chain of strategic metals such as tungsten. To combat this, the U.S. Defense Department is starting a new grants program to help develop a processing facility at Mountain Pass in California, currently the only U.S. located mine for rare-earths materials. However, U.S. medical manufacturers need more supply, and soon.
New Tungsten Production Will Open the Global Supply Chain
Other new entrants into the market have begun mining projects throughout the world that are mining for tungsten. These efforts are critically important to increase supply levels and exports back to the U.S., which will benefit the overall global supply chain of tungsten for production and manufacturing and would enable the U.S. to depend on its own medical manufacturing supply.
The Korea Tungsten project located in the Sangdong Mine of South Korea hosts one of the largest tungsten resources in the world. This mine was the leading global tungsten producer for more than 40 years and it has the potential to produce 50% of the non-Chinese world’s tungsten supply. The project has become a center of focus recently for resource experts, miners, investors, shareholders, and other interested parties around the globe.
Without access to rare-earths such as Tungsten found in locations such as the Sangdong Mine, the consequences of a continued strained supply of these metals would be disastrous to the U.S. healthcare system, particularly during the COVID-19 pandemic. As a result, opening the supply chain for these rare-earths will help alleviate any medical supply threats that continue to grow from China and its long-held dominance of the market.
Hopefully, the Sangdong Mine is one example of relief U.S. and global medical manufacturers will see from the mining and production of tungsten in an effort to ease the supply chain of this precious raw material, which is sorely needed for some of today’s most important healthcare uses.
Almonty Industries Reports Fourth Quarter and Full Year 2025 Financial Results
Almonty today announced its financial results for the three and twelve months ended December 31, 2025.
Almonty Completes Phase 1 of Sangdong Tungsten Mine in South Korea
Almonty today announced the completion of Phase 1 commissioning at its Sangdong Tungsten Mine in Gangwon Province, South Korea – marking the return to production after more than 30 years.
About Almonty
Almonty (NASDAQ: ALM) (TSX: AII) (ASX: AII) (FSE: ALI1) is a leading supplier of conflict free tungsten – a strategic metal critical to the defense and advanced technology sectors. As geopolitical tensions heighten, tungsten has become essential for armor, munitions, and electronics manufacturing. Almonty’s flagship Sangdong Tungsten Mine in South Korea, historically one of the world’s largest and highest-grade tungsten deposits, is expected to supply over 80% of global non-China tungsten production upon reaching full capacity, directly addressing critical supply vulnerabilities highlighted by recent U.S. defense procurement bans and export restrictions by China. With established operations in Portugal and additional projects in Spain, Almonty is strategically aligned to meet rapidly rising demand from Western allies committed to supply-chain security and defense readiness. To learn more, please visit almonty.com.
Legal Notice
The release, publication, or distribution of this announcement in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this announcement is released, published, or distributed should inform themselves about and observe such restrictions. Neither the TSX nor its Regulation Services Provider (as that term is defined in the policies of the TSX) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Information
This news release contains “forward-looking statements” and “forward-looking information” within the meaning of applicable securities laws.
All statements, other than statements of present or historical facts, are forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and assumptions and accordingly, actual results could differ materially from those expressed or implied in such statements. You are hence cautioned not to place undue reliance on forward-looking statements. Forward-looking statements are typically identified by words such as “plan”, “development”, “growth”, “continued”, “intentions”, “expectations”, “emerging”, “evolving”, “strategy”, “opportunities”, “anticipated”, “trends”, “potential”, “outlook”, “ability”, “additional”, “on track”, “prospects”, “viability”, “estimated”, “reaches”, “enhancing”, “strengthen”, “target”, “believes”, “next steps” or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements in this news release include, but are not limited to, statements concerning the completion of the Offering, the Company’s redomiciling initiatives, the Company’s position as a leading supplier of tungsten to the U.S. and its allies, the timing of any listing of the Common Shares on the Nasdaq, the continued listing of the Common Shares on the TSX and the ASX and trading on the Frankfurt Stock Exchange, and the use of proceeds of the Offering.
Forward-looking statements are based upon certain assumptions and other important factors that, if untrue, could cause actual results to be materially different from future results expressed or implied by such statements. There can be no assurance that forward-looking statements will prove to be accurate. Key assumptions upon which the Company’s forward-looking information is based include, without limitation, the absence of market conditions that could adversely impact the Offering or the intended listing of the Common Shares on the Nasdaq; the satisfaction of all listing requirements of the Nasdaq and continued listing requirements of the TSX and ASX; the achievement of any closing conditions to the Offering; and the absence of material adverse changes in the Company’s industry or the global economy including interest rates, inflationary pressures, supply chain disruptions, and commodity market volatility.
Forward-looking statements are also subject to risks and uncertainties facing the Company’s business, including, without limitation, the risks and uncertainties identified in the Registration Statement; risks relating to the Offering not being completed in a timely manner or at all, including due to unfavourable market or other conditions or factors; the possibility that the required approvals for or conditions to the Offering will not be received or satisfied on a timely basis or at all; changes in the anticipated timing for closing the Offering; business disruption during the pendency of or following the Offering; diversion of management time on Offering-related issues; the ability to retain members of Almonty’s management team; the impact of the Offering on relationships with customers, suppliers, employees and other business counterparties; risks related to the reaction of customers, shareholders and members of the public to the Offering; and other events that could adversely impact the completion of the Offering, including industry or economic conditions outside of Almonty’s control. Any of these risks could have a material adverse effect on the Company’s business, financial condition, results of operations and growth prospects. Readers should consider reviewing the detailed risk discussion in the Company’s Registration Statement, the most recent Annual Information Form and the amended Management Discussion and Analysis for the three months ended March 31, 2025 filed on SEDAR+, for a fuller understanding of the risks and uncertainties that affect the Company’s business and operations.
Although Almonty has attempted to identify important factors that could cause actual results, level of activity, performance or achievements to differ materially from those contained in forward-looking statements, there may be other factors that cause results, level of activity, performance or achievements not to be as anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate and even if events or results described in the forward-looking statements are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, Almonty. Accordingly, readers should not place undue reliance on forward-looking statements and are cautioned that actual outcomes may vary.
Investors are cautioned against attributing undue certainty to forward-looking statements. Almonty cautions that the foregoing list of material factors is not exhaustive. When relying on Almonty’s forward-looking statements and information to make decisions, investors and others should carefully consider the foregoing factors and other uncertainties and potential events. Almonty has also assumed that material factors will not cause any forward-looking statements and information to differ materially from actual results or events. However, the list of these factors is not exhaustive and is subject to change and there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.
THE FORWARD-LOOKING INFORMATION CONTAINED IN THIS PRESS RELEASE REPRESENTS THE EXPECTATIONS OF ALMONTY AS OF THE DATE OF THIS PRESS RELEASE AND, ACCORDINGLY, IS SUBJECT TO CHANGE AFTER SUCH DATE. READERS SHOULD NOT PLACE UNDUE IMPORTANCE ON FORWARD- LOOKING INFORMATION AND SHOULD NOT RELY UPON THIS INFORMATION AS OF ANY OTHER DATE. WHILE ALMONTY MAY ELECT TO, IT DOES NOT UNDERTAKE TO UPDATE THIS INFORMATION AT ANY PARTICULAR TIME, WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE, EXCEPT AS REQUIRED IN ACCORDANCE WITH APPLICABLE LAWS.
For further information, please contact:
Lewis Black
Chairman, President and CEO
Telephone: +1 647-438-9766
Email: [email protected]